COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

Even as we struggle with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $240.05 million in 65 projects around the world.











focused on new classes


The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More

Spotlight on Science

T2 Biosystems’ diagnostic panel can identify superbug drug resistance days faster than current methods

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.


UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners




Boston, MA

Live Webinar: GARDP/REVIVE – The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study


Basel, Switzerland

BIOCOM 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics


  • 06.30.2020  |  CARB-X funds Eligo Bioscience to develop CRISPR-based therapeutics derived from bacteriophages to kill superbugs and prevent deadly infections in transplant patients full release

  • 06.22.2020  |  CARB-X funds University of Queensland to accelerate the development of a new class of last-resort antibiotics to treat deadly superbug infections full release

  • 06.22.2020  |  CARB-X expands awards to Amicrobe by $4.6M to accelerate development of two distinct Amicidin-β topical antimicrobial products full release

See All News

In The News

  • 06.24.2020  |  CARB-X-funded Vaxcyte (formerly Sutrovax) has announced the closing of its Initial Public Offering (IPO) full story

  • 06.24.2020  |  Saving Antibiotics: It will take more than science to keep these life-saving drugs from becoming treatments of the past full story

  • 06.14.2020  |  HelixBind awarded $3 million grant from NIH to expand its diagnostic platform full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.